Multiple innovative approaches in oncology aim to improve patient outcomes. Wholomics has developed a metabolomics platform enabling multi-cancer detection via serum analysis, providing enhanced sensitivity for early-stage tumors. Plus Therapeutics plans to relaunch its CNSide assay for detecting central nervous system metastases in cancer patients. Additionally, AI-driven imaging tools predict lung cancer pathological responses, and a novel T-cell engager targeting LGR5 advances as a clinical candidate for solid tumors. These developments underscore ongoing efforts to refine cancer diagnostics and targeted immunotherapies.